KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Sales (2016 - 2025)

Rigel Pharmaceuticals has reported Return on Sales over the past 15 years, most recently at 0.04% for Q4 2025.

  • For Q4 2025, Return on Sales rose 4.0% year-over-year to 0.04%; the TTM value through Dec 2025 reached 0.01%, up 1.0%, while the annual FY2025 figure was 0.01%, 1.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.04% at Rigel Pharmaceuticals, up from 0.0% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.04% in Q4 2025 and troughed at 0.02% in Q1 2022.
  • A 5-year average of 0.0% and a median of 0.0% in 2023 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: fell -2bps in 2022 and later increased 4bps in 2025.
  • Year by year, Return on Sales stood at 0.01% in 2021, then skyrocketed by 102bps to 0.0% in 2022, then decreased by -25bps to 0.0% in 2023, then skyrocketed by 1109bps to 0.0% in 2024, then surged by 1442bps to 0.04% in 2025.
  • Business Quant data shows Return on Sales for RIGL at 0.04% in Q4 2025, 0.0% in Q3 2025, and 0.01% in Q2 2025.